Niclosamide

Category: compound

An FDA-approved anthelmintic being repurposed for cancer. Inhibits multiple oncogenic pathways including Wnt, STAT3, and NF-κB.

Mechanism Detail

Niclosamide uncouples oxidative phosphorylation in mitochondria, inhibits Wnt/β-catenin transcriptional activity, blocks STAT3 phosphorylation, and induces autophagy. It also inhibits the Notch signaling pathway. These multi-target effects make it attractive for cancers with pathway redundancy.

Clinical Status

Phase I/II trials for colorectal cancer and prostate cancer. Bioavailability is limited by poor oral absorption. Reformulation efforts (niclosamide ethanolamine) aim to improve systemic exposure.

Relevant Diseases

Relevant Therapies

Related Terms